Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 EUR | -1.41% | -3.45% | -11.11% |
06/03 | Herantis Pharma Oyj Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
06/03 | Transcript : Herantis Pharma Oyj, 2023 Earnings Call, Mar 06, 2024 |
Sales 2024 * | 1.3M 1.39M 116M | Sales 2025 * | - | Capitalization | 28.23M 30.13M 2.51B |
---|---|---|---|---|---|
Net income 2024 * | -3M -3.2M -267M | Net income 2025 * | -4M -4.27M -356M | EV / Sales 2024 * | 18.5 x |
Net cash position 2024 * | 4.2M 4.48M 374M | Net cash position 2025 * | - 0 0 | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-
| P/E ratio 2025 * |
-
| Employees | 10 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 69.93% |
Latest transcript on Herantis Pharma Oyj
1 day | -1.41% | ||
1 week | -3.45% | ||
Current month | -0.36% | ||
1 month | -0.36% | ||
3 months | -5.41% | ||
6 months | -16.67% | ||
Current year | -11.11% |
Managers | Title | Age | Since |
---|---|---|---|
Founder | - | 01/08/01 | |
Antti Vuolanto
CEO | Chief Executive Officer | - | 12/18/12 |
Tone Kvåle
DFI | Director of Finance/CFO | 55 | 26/20/26 |
Members of the board | Title | Age | Since |
---|---|---|---|
Director/Board Member | 53 | 01/14/01 | |
Director/Board Member | 53 | 11/20/11 | |
Chairman | 64 | 01/12/01 |
Date | Price | Change | Volume |
---|---|---|---|
30/24/30 | 1.4 | -1.41% | 5,376 |
29/24/29 | 1.42 | -2.74% | 17,868 |
26/24/26 | 1.46 | +2.10% | 9,116 |
25/24/25 | 1.43 | -4.35% | 14,381 |
24/24/24 | 1.495 | +1.36% | 37,018 |
Delayed Quote Nasdaq Helsinki, April 30, 2024 at 05:04 pm IST
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-11.11% | 30.18M | |
-3.46% | 102B | |
+1.41% | 96.09B | |
+2.13% | 22.28B | |
-15.84% | 21.4B | |
-9.30% | 18.14B | |
-39.98% | 17.02B | |
-14.65% | 16.09B | |
+4.39% | 13.83B | |
+31.35% | 11.97B |
- Stock Market
- Equities
- HRTIS Stock